Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Document › Details

Evolva S.A.. (3/24/21). "Press Release: Evolva Announces New Chief Financial Officer". Reinach.

Organisations Organisation Evolva Holding SA (SIX: EVE)
  Group Evolva (Group)
  Organisation 2 Lonza Consumer Health & Nutrition (division)
  Today Lonza Pharma Biotech & Nutrition (LPBN) (segment)
  Group Lonza (Group)
Products Product food ingredient
  Product 2 industrial biotechnology
Persons Person Däweritz, Carsten (Evolva 202104 CFO before almost 20y at Lonza)
  Person 2 Walker, Oliver (Evolva 201807– CEO before CFO before Sivantos + Nobel Biocare + Sonova + Stratec)

Evolva (SIX:EVE) announced today that Carsten Däweritz has been appointed Chief Financial Officer. He will report to Oliver Walker, CEO of Evolva, and will join the Management Team of the company effective April 16, 2021.

Oliver Walker, CEO of Evolva, said: «I'm pleased that Carsten has accepted the role of CFO at Evolva. Carsten has extensive leadership experience in financial positions. He has our full support and confidence as we continue to grow the business.»

Regarding his appointment, Carsten said: «I'm honored and excited to be given the opportunity to join one of the promising biotech businesses.»

Carsten Däweritz has broad financial experience in the pharma and biotech industry. Before joining Evolva, Carsten spent almost 20 years at Lonza in a variety of financial leadership positions. Most recently, he was Global Head Controlling of the Consumer Health & Nutrition Business at Lonza.

Carsten is a Swiss and German citizen. He has a Bachelor in Mathematics and holds a Master in Business Administration from the University of Münster, Germany.

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva's employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at

For Evolva multi media content, please visit:


This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


Barbara Duci
Head of Investor and Corporate Relations
+41 61 485 2003
+41 79 739 2636

Record changed: 2021-04-09


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for Evolva (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Global Partnering Four Events One Price 650x80

» top